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Abstract
Semiconductor quantum dots (Qdots) have been utilised as probes in fluorescence microscopy and provide an alternative to fluores-
cent dyes and fluorescent proteins due to their brightness, photostability, and the possibility to excite different Qdots with a single
wavelength. In spite of these attractive properties, their implemenation by biologists has been somewhat limited and only a few
Qdot conjugates are commercially available for the labelling of cellular targets. Although many protocols have been reported for
the specific labelling of proteins with Qdots, the majority of these relied on Qdot-conjugated antibodies synthesised specifically by
the authors (and therefore not widely available), which limits the scope of applications and complicates replication. Here, the speci-
ficity of a commercially available, Qdot-conjugated secondary antibody (Qdot-Ab) was tested against several primary IgG anti-
bodies. The antigens were labelled simultaneously with a fluorescent dye coupled to a secondary antibody (Dye-Ab) and the Qdot-
Ab. Although, the Dye-Ab labelled all of the intended target proteins, the Qdot-Ab was found bound to only some of the protein
targets in the cytosol and could not reach the nucleus, even after extensive cell permeabilisation.
Introduction
Quantum dots (Qdots) are nanometre-sized semiconductor
nanocrystals that typically consist of a metallic core of
cadmium selenium (CdSe) and an inorganic zinc sulfide (ZnS)
shell and have been applied as fluorescent probes for the
labelling of biological structures [1,2]. To make Qdots water
soluble, and thus suitable for biological applications, their sur-
face is modified either by coating with hydrophilic ligands
(such as poly(ethylene glycol) (PEG) [3,4]) or they are encapsu-
lated in amphiphilic polymers [5]. Antibodies that recognise
specific biological targets can then be conjugated to these Qdots
for use in immunofluorescence. Conventional immunocyto-
chemistry (ICC) protocols involve the chemical fixation of
Beilstein J. Nanotechnol. 2017, 8, 1238–1249.
1239
cells, followed by permeabilisation with a detergent. This
creates pores in the cell membrane, allowing primary and sec-
ondary antibodies to gain access to the protein of interest.
Qdots are an attractive alternative to traditional fluorescent dyes
for ICC because they are much brighter and more photostable
[6,7]. In contrast to fluorescent dyes, Qdots can be excited with
a wide range of wavelengths and have narrow emission spectra,
which is advantageous for multiplex imaging [8,9]. The
emission maxima of Qdots are dependent on their size; the
emission peak for large Qdots is in the red end of the spectra
and smaller Qdots in the blue region [1]. Qdots are also an ideal
probe choice for super-resolution imaging techniques that
require stochastic optical fluctuation, as they exhibit well-char-
acterised blinking between fluorescent and non-fluorescent
states [10,11].
Despite these favourable characteristics, the overall hydrody-
namic radius of a Qdot (15–20 nm) is much larger than that of a
fluorescent dye molecule [12-14]. As a result, one large Qdot
may host many antibodies, whereas many fluorescent dye mole-
cules can be coupled to a single antibody [9,15]. Furthermore,
the overall size of commercially available Qdots is further
enlarged by the addition of protective layers to maintain
stability and shelf life [13,16]. Qdot-conjugated antibodies
(Qdot-Abs) are therefore unlikely to replace fluorescent dyes in
ICC due to their inferior penetration capability [17,18]. Despite
the assumption that manufactured Qdots are quality controlled,
the considerable batch-to-batch variability means that each time
a new lot is purchased, the labelling conditions need to be opti-
mised [19]. The use of commercial Qdot-Abs is also expensive,
as they are used in quantities on the order of 20 nM, yet are
supplied at a higher price per unit volume compared to fluores-
cent dyes [16,20,21]. Despite having been around for several
decades, Qdots are rarely used in routine ICC [1].
There are some notable examples of Qdot-Abs in the published
literature where they have been used to label glycine receptors
[22], glial fibrillary acidic proteins (GFAPs) [12], mortalin [23],
erythrocytes [24], GRP78 protein [25], caveolin-1 [26], golgi
[20], and nuclear HER2 targets [6]. The majority of this
labelling, however, was done with in-house synthesised Qdots
rather than commercially available Qdots [27]. The use of com-
mercially available Qdots allows for the controlled synthesis
and thus the size of the Qdot-Abs can be kept to a minimum.
However, it has been noted that specific labelling of nuclear and
some cytoplasmic structures with Qdot-Abs is not always repro-
ducible [1,6,13,20,28]. Another concern amongst users of com-
mercial Qdot-Abs is non-specific labelling and the formation of
aggregates, which may introduce artifacts and lead to misinter-
pretation of false positive results [12,13].
Figure 1: Strategies for immunofluorescence labelling. A fluorescent
label (green) is conjugated to a secondary antibody (grey) or directly to
a primary antibody (black), containing antigen-binding sites (red),
which recognises and binds to a specific antigen (pink). Immunofluo-
rescence labelling was either indirect with a primary antibody and a
Qdot 625/Qdot 525 (Qdot-Ab) (A) or fluorescent dye such as Alexa
Fluor 488/Cyanine 3 (Dye-Ab) (B) conjugated to a secondary antibody,
or direct with an anti-GFP primary antibody conjugated to Qdot 625
(Qdot 625-GFP) (C). An alternative Qdot 625 was tried for indirect
immunofluorescence labelling using a Qdot 625 streptavidin (yellow)
conjugate (Qdot-Streptavidin) and biotinylated (blue) primary antibody
(D). Scale bar is 10 nm.
Here, we focus on the specificity of commercially available
Qdot 625 conjugated antibodies (Thermo Fisher Scientific,
UK), with an emission maxima of 625 nm (excitation and emis-
sion spectra available in Figure S1 in Supporting Information
File 1), in fixed cells (Figure 1). Different protein targets were
labelled simultaneously with both a secondary antibody conju-
gated to a fluorescent dye (Dye-Ab) and a Qdot 625 conjugated
secondary antibody (Qdot 625-Ab). A Qdot 525 conjugated sec-
ondary antibody (Qdot 525-Ab) was also evaluated, with an
emission maxima of 525 nm (excitation and emission spectra
available in Supporting Information File 1, Figure S2); along
with an anti-GFP Qdot 625 conjugate (Qdot 625-GFP), anti-
tubulin Qdot 625 conjugate (Qdot 625-Tubulin), and Qdot 625
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Figure 2: Specific labelling of fibronectin with Qdots. Fixed rat mammary (Rama) 27 fibroblasts were dual labelled with green Alexa Fluor 488 (A) and
a red Qdot 625 (B) to produce an overlaid wide-field image (C). Scale bar is 20 μm.
conjugated to streptavidin (Qdot-Streptavidin). We found
that while the prototypical target of Qdot-Abs: tubulin, could
be easily labelled, several other protein targets including
nuclear proteins and components of large cytosolic protein com-
plexes could not be labelled with Qdot-Abs. We posit that this
may be due to steric hindrance associated with the size of the
Qdot-Abs.
Results and Discussion
Labelling of extracellular antigens: To investigate the speci-
ficity of commercial Qdot-Abs for intracellular targets, differ-
ent types of proteins were stained simultaneously with conven-
tional Dye-Abs and Qdot-Abs and imaged using an epifluores-
cence microscope. To eliminate the possibility of competition
between the Dye-Abs and Qdot-Abs, for the antigen binding
sites, which could affect the labelling, samples were also pre-
pared separately with either a Dye-Ab or Qdot-Ab. A Qdot 625-
Ab concentration of 20 nM was used, as it has been shown that
a high concentration of Qdot-Abs improves specific labelling
and signal-to-noise ratio [21]. Initially, to assess the labelling
efficiency of Qdot-Abs, the extracellular matrix (ECM) protein
fibronectin was dual labelled with Qdot 625-Ab and Dye-Ab
(Alexa Fluor 488). Fibronectin is abundant at the cell surface
and therefore, would not be expected to display any artifacts as-
sociated with accessibility. Indeed, in this case similar labelling
was achieved with Qdot 625 and Alexa Fluor 488 (Figure 2).
Labelling of cytosolic structures: The vast majority of studies
using Qdots show tubulin staining [6,12,16,18,20], therefore we
sought to label this abundant cytosolic protein in order to have a
positive control for our labelling protocol. After incubation
with an anti-tubulin primary antibody and a Qdot 625-Ab, we
once again found labelling which was comparable to samples
(simultaneously or separately) labelled with Alexa Fluor 488
(Figure 3).
To investigate whether the same structure (microtubules) could
be labelled with a different fluorophore-antibody conjugate,
direct ICC was performed using a Qdot 625 conjugated directly
to an anti-GFP primary antibody (see Methods for details).
Cells expressing tubulin-GFP were labelled with the anti-GFP
Qdot 625 conjugate (Qdot 625-GFP) and gave similar results to
those imaged with indirect ICC (Figure 3). By inspection it was
clear, that β-tubulin had been labelled with Qdot 625
(Figure 3C), however, to compare the two labelling techniques,
an intensity correlation plot was produced (Figure 3D). A
Pearson’s correlation coefficient (r2) value of 0.93 suggested
that there was an almost perfect correlation between Qdot 625
and Alexa Fluor 488 labelled microtubules. In addition, the
degree of co-localisation was measured using the Manders coef-
ficient [29]. The average Manders coefficient of Alexa Fluor
488 overlapping with Qdot 625 (M1) was 0.99 (SD = 0.007,
N = 3) and Qdot 625 overlapping with Alexa Fluor 488 (M2)
was 0.99 (SD = 0.005, N = 3), confirming that the correlation
between Qdot 625 and Alexa Fluor 488 was very good. In addi-
tion, an anti-tubulin primary antibody was also conjugated to
Qdot 625 (Qdot 625-Tubulin) (Figure S3 in Supporting Infor-
mation File 1). A negative control containing Alexa Fluor
488-Ab and Qdot 625-Ab only, with no anti-tubulin primary
antibody was also prepared, showing negligible unspecific
binding of Alexa Fluor 488 and Qdot 625 to HeLa cells (Figure
S4 in Supporting Information File 1).
Labelling intracellular complexes: Both fibronectin and
β-tubulin are highly abundant proteins. Furthermore, their anti-
gens are relatively accessible. We therefore, looked to antigens
present in more complex intracellular structures, including the
focal adhesion protein talin and nuclear splicer marker SC35.
Talin exists in a dynamic equilibrium with both a bound pool
(forming focal adhesions) and a cytosolic pool. Using the same
primary antibody, Alexa Fluor 488 labelled both the cytosolic
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Figure 3: Specific labelling of tubulin with Qdots. Methanol-fixed HeLa cells were labelled indirectly with a primary anti-tubulin antibody, green Alexa
Fluor 488 (A), and red Qdot 625 (B), to produce an overlaid wide-field image (C). As a measure of co-localisation between Alexa Fluor 488 and Qdot
625, fluorescence intensities of the overlaid wide-field image (C) were analysed using a custom-written Matlab code to produce a correlation scatter
plot (D). Pearson’s correlation coefficient (r2) of 0.93 indicates very high correlation. The average Manders coefficient of Alexa Fluor 488 overlapping
with Qdot 625 (M1) was 0.99 (SD = 0.007, N = 3) and the average Manders coefficient of Qdot 625 overlapping with Alexa Fluor 488 (M2) was 0.99
(SD = 0.005, N = 3, as determined using JACoP. Paraformaldehyde fixed TC7 cells, expressing tubulin-GFP (E), were also labelled directly with an
anti-GFP Qdot 625 conjugate (F) to produce an overlaid wide-field image (G,) and a corresponding correlation scatter plot (H); with a Pearson’s corre-
lation coefficient (r2) of 0.86. Scale bar is 20 μm.
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1242
Figure 4: Non-specific labelling of talin with Qdots. Fixed HeLa cells were dual labelled with green Alexa Fluor 488 (A) and red Qdot 625 (B) to
produce an overlaid wide-field image (C). Scale bar is 20 μm.
pool of talin and the bound pool forming focal adhesions,
whereas Qdot 625 appeared to only label the cytosolic regions
(Figure 4). At the same time, a control sample was prepared,
consisting of HeLa cells incubated simultaneously with an
Alexa Fluor 488-Ab and Qdot 625-Ab, without prior addition of
an anti-talin primary antibody (Figure S5 in Supporting Infor-
mation File 1). Here, it appears that the low signal of Qdot 625,
is an indication that that the Qdot 625-Ab actually binds non-
specifically to cells.
Unlike β-tubulin and talin, SC35 is not only intracellular, but
contained within the nucleus, which is crowded with deoxyri-
bonucleic acid (DNA) and proteins. Under conditions identical
to the previous experiments, the labelling of SC35 with the
Qdot 625-Ab was non-specific, diffuse, and predominately
cytosolic (Figure 5). The intensity correlation of Qdot 625 and
Alexa Fluor 488 labelling of SC35 was assessed by plotting
fluorescence intensities (Figure 5D) within the overlaid image
(Figure 5C). A Pearson’s correlation coefficient (r2) value of
0.006 suggested that there was practically no correlation be-
tween Qdot 625 and Alexa Fluor 488 signals. Once more, the
degree of co-localisation was quantified using the Manders’
coefficient. The average Manders’ coefficient of Alexa Fluor
488 overlapping with Qdot 625 (M1) was 0.19 (SD = 0.035,
N = 3) and the average Manders’ coefficient of Qdot 625 over-
lapping with Alexa Fluor 488 (M2) was 0.08 (SD = 0.031,
N = 3), which confirms that the labelling of SC35 with Qdot
625 showed no co-localisation with Alexa Fluor 488. To control
for non-specific binding of the Qdot 625-Ab to cells, a negative
control was introduced, whereby the cells were incubated with
the Qdot 625-Ab only (Figure S6 in Supporting Information
File 1). In the absence of a primary antibody, there was negli-
gible labelling detected with the Qdot 625-Ab, which suggests
that the SC35 cytosolic signal is due to the presence of minority
pool of SC35 in the cytosol.
Optimising sample preparation: Since Qdot-Abs may be
sensitive to certain fixation protocols [13,19,30], as well as
using paraformaldehyde, ice cold methanol was also tried.
Methanol fixation and harsher permeabilisation with up to 1%
Triton X-100 was used in an attempt to increase accessibility of
the Qdots to complex intracellular antigens. Although methanol
fixation gave better signal-to-noise ratio and specific Qdot 625
labelling of β-tubulin (Figure 3B), without the need for further
permeabilisation, there was non-specific labelling observed for
talin and SC35.
Size limiting access to the nucleus: We suspected that the size
of the commercial Qdot 625-Ab and the associated accessi-
bility to targets was the reason behind the inability to label com-
plex cytosolic and nuclear structures. Although, the manufac-
turer (Thermo Fisher Scientific, UK) has approximated that
Qdot 625 (17 nm) has an overall hydrodynamic size of 30 nm
with a couple of antibodies per Qdot, we have provided our own
measurements of Qdot 625 in the Supporting Information
File 1. We attempted to measure the size of Qdot 625 using dif-
ferent methods: transmission electron microscopy (TEM), size-
exclusion high-performance liquid chromatography (SEC-
HPLC), and fluorescence correlation spectroscopy (FCS). The
TEM and SEC-HPLC results are in agreement with the
provider’s data, giving a core size of ≈8 nm (Figure S7 in Sup-
porting Information File 1) and a hydrodynamic diameter of
≈15 nm (Figure S8 in Supporting Information File 1), respec-
tively. However, the FCS results indicate a much larger size of
≈76.84 nm for the Qdot 625-Ab (Figure S9 in Supporting Infor-
mation File 1), suggesting some degree of Qdot aggregation (al-
though this is not seen in the SEC-HPLC nor in the TEM data).
Due to the discrepancy observed for Qdot 625-Ab, using differ-
ent methods, we decided to take FCS measurements for a
presumably smaller green Qdot 525-Ab. The size obtained for
the Qdot 525-Ab was more compatible with the provider’s data
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Figure 5: Non-specific labelling of SC35 with Qdots. Fixed HeLa cells were dual labelled with green Alexa Fluor 488 (A) and red Qdot 625 (B) to
produce an overlaid wide-field image (C). Scale bar is 20 μm. As a measure of co-localisation between Alexa Fluor 488 and Qdot 625, fluorescence
intensities of the overlaid wide-field image (C) were analysed using a custom-written Matlab code to produce a correlation scatter plot (D). Pearson’s
correlation coefficient (r2) of 0.006 indicates no co-localisation. The average Manders' coefficient of Alexa Fluor 488 overlapping with Qdot 625 (M1)
was 0.19 (SD = 0.035, N = 3) and the average Manders’ coefficient of Qdot 625 overlapping with Alexa Fluor 488 (M2) was 0.08 (SD = 0.031, N = 3),
as determined using JACoP.
at 41.72 nm (Figure S10 in Supporting Information File 1).
ATTO488 (Figure S11 in Supporting Information File 1) was
used to calibrate the confocal volume and fluorescent latex
beads (Figure S12 in Supporting Information File 1), of a
known size, were used as a standard to compare against Qdot-
Abs (For methods see Supporting Information File 1). These
results are robust and reproducible (including two different
batches of Qdot 625-Ab).
Labelling with alternative Qdot-Abs: A Qdot 525 conjugated
secondary antibody (Qdot 525-Ab), with presumably smaller
dimensions, was further tried against the same anti-tubulin pri-
mary antibody (Figure S13 in Supporting Information File 1),
anti-talin primary antibody (Figure S14 in Supporting Informa-
tion File 1), and anti-SC35 primary antibody (Figure S15 in
Supporting Information File 1), with the similar results ob-
tained as for Qdot 625-Ab. An alternative Qdot 625 conjugated
to the biotin-binding protein streptavidin (Qdot-Streptavidin)
(Thermo Fisher Scientific, UK) was also evaluated. To test the
specificity of Qdot-Streptavidin for nuclear targets, a transcrip-
tion factor, which localises in the nucleus as speckles (sub-
nuclear foci), known as hypoxia inducible factor two alpha
(HIF2α) was labelled. Fixed HeLa cells were transfected with
HIF2α tagged with the fusion protein EGFP (EGFP-HIF2α), in-
cubated with anti-GFP biotin primary antibody, and Qdot-Strep-
tavidin. All of the endogenous biotin sites in the cell were
blocked before addition of the biotinylated anti-GFP primary
antibody with an endogenous biotin-blocking kit (Thermo
Fisher Scientific, UK). Similar results were obtained as previ-
ously for Qdot 625-Ab, with Qdot-streptavidin binding to any
cytosolic pool of HIF2α without labelling the distinct speckles
in the nucleus (Figure 6). Since the transfected cells have a
cytosolic pool of EGFP-HIF2α, this was labelled by Qdot-strep-
tavidin more than in the untransfected cells, where there was no
GFP present; hence the very bright fluorescent Qdot signal in
the cytosol.
Assessing nuclear accessibility of Qdots: Fluorescent in situ
hybridisation (FISH) is another application where specific intra-
cellular targeting is required. Like many applications, FISH
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Figure 6: Partial labelling of HIF2α with Qdot-Streptavidin. Fixed HeLa cells were transfected with EGFP-HIF2α (A), incubated with a primary anti-
GFP biotinylated antibody and Qdot 625 streptavidin conjugate (Qdot-Streptavidin) (B), to produce an overlaid image (C). Scale bar is 20 µm.
benefits from bright photostable probes, and indeed several
studies have been published using Qdots for FISH [31]. Much
of the FISH data however, describe metaphase chromosomes
(where breakdown of the nuclear envelope has occurred) or
chromosomal spreads devoid of cell membranes altogether [32-
34]. Furthermore a 2009 appraisal of the use of Qdots for FISH
considers them unsuitable in their current form "… because of
the lack of reproducibility of the experiments" when using these
materials [35]. Interestingly, in all of our Qdot 625 images,
even when the staining was non-specific, there was no labelling
within the nucleus (Figure 2–6). This suggested that, specificity
issues aside, the Qdot-Abs could not access the nucleus at all.
This hypothesis was tested by transfecting cells with an uncon-
jugated soluble GFP, which diffuses throughout the cytoplasm
and nucleus. We then labelled with either a direct anti-GFP
Qdot 625 conjugate (Qdot-GFP) or indirectly with a primary
anti-GFP antibody and Qdot 625-Ab. Both approaches yielded
homogenous labelling in the cytosol, with the Qdot signal being
excluded from the nucleus (Figure 7). There was also little non-
specific Qdot 625 staining in the non-transfected cells (Figures
S16 and S17 in Supporting Information File 1). Unlike Qdot
625, when the unconjugated soluble GFP was immunolabelled
with a secondary antibody coupled to the fluorescent dye
cyanine 3 (Cy3), there was labelling in both the cytosol and
nucleus (Figure 7E). To assess the extent at which Qdot 625 did
not label soluble GFP within the nucleus, fluorescence intensi-
ties of Qdot 625 and GFP were plotted from line scans taken
across a section of the cell, including the cytosolic region and
nucleus (Figure 7K). There was an obvious decline in the fluo-
rescence intensity of Qdot 625 in the nucleus. Under continu-
ous illumination, the fluorescence intensity of Qdot 625 in the
cytosol was greater than that of GFP, due to the superior bright-
ness of Qdots. Multichannel images were taken without adjust-
ment to the focus to rule out different focal planes explaining
the absence of Qdots from the nucleus.
Conclusion
Fluorescent Qdots are bright and photostable and hence have
been promoted as having significant potential for imaging in
biology, including for the immunolabelling of cellular struc-
tures. However, even after several years of promising articles
and reviews, Qdots have not found routine use in biological
research. Here, we examine the performance of some of the few
Qdot conjugates commercially available for immunofluores-
cence (Table S1 in Supporting Information File 1). While all
tested antigens could be labelled using antibodies conjugated to
fluorescent dyes (Dye-Abs) (e.g. Alexa Fluor 488), only tubulin
and extracellular fibronectin could be labelled specifically with
Qdot-Abs. Neither a nuclear protein (SC35) nor an antigen
within a large complex (talin) could be labelled with the
Qdot-Abs. Our hypothesis is that the specificity of Qdot-Abs
is dependent upon the type of protein, its abundance, and loca-
tion within the cell. This is most likely due to the size of the
Qdot-Abs, leading to steric hindrance and limited access to
certain epitopes. Additionally, if cross-linking of the target pro-
tein has occurred, Qdot 625 aggregates may restrict access to
the epitope and thus affect the specific labelling of these pro-
teins [36].
Therefore, we conclude that these Qdot-Abs are not suitable to
detect complex intracellular structures unless the proteins are
abundant and have multiple, accessible antigens along the
structure. Although Montón et al. suggest that Qdot-Abs
were more specific for proteins that are scarce in the cell [20],
here we find that the specific labelling of proteins such as SC35
and talin could not be achieved with the with commercial Qdot-
Abs.
The parameters that may affect the ability of Qdots to penetrate
intracellular targets (such as foci adhesion complexes or nuclear
proteins) include the labelling ratio between Qdots and func-
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Figure 7: Qdot-Abs are unable to access the cell nucleus. Fixed HeLa cells were transfected with unconjugated soluble GFP (A), incubated with a pri-
mary anti-GFP antibody, and red Qdot-Ab (B) to produce an overlaid image (C). Fixed HeLa cells were also transfected with unconjugated soluble
GFP (D), incubated with a primary anti-GFP antibody, and red cyanine 3 conjugated to a secondary antibody (E) to produce an overlaid image (F).
Direct ICC was done by incubating fixed HeLa cells, transfected with unconjugated soluble GFP (G), with an anti-GFP Qdot 625 conjugate (H) to
produce an overlaid image (I). Normalised fluorescence intensities of unconjugated soluble GFP labelled with Cy3 (J) and Qdot 625 (K) were plotted
from corresponding lines scans to show no labelling within the nucleus with Qdot 625. Scale bar is 20 μm.
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tional antibodies, the overall surface charge of Qdot-Ab conju-
gates, and whether there is a presence of a protein corona. The
labelling ratio of Qdots to antibodies present within commer-
cially available Qdot-Ab conjugates has been previously evalu-
ated, where the non-specific labelling of proteins was attributed
to the lack of IgG molecules per Qdot [37]. Depending on the
chosen Qdot-Ab conjugation method, the binding affinity of the
antibody for the Qdots can be increased. However, regardless of
the variability in the Qdot synthesis and antibody conjugation
protocols, the orientation in which the IgG molecules bind to
Qdots cannot be controlled [37]. The binding affinity of Qdot-
Abs can also be affected by the surface charge they possess. For
instance, positively charged Qdots are taken up by cells more
readily than negatively charged or zwitterionic Qdots, which
suppress protein adsorption and thus the formation of a protein
corona [38]. Qdots with a zwitterionic surface have a zeta
potential of near zero, are resistant to non-specific binding onto
cells, and have a high colloidal stability [39]. Commercially
available Qdot-Abs evaluated in this report were used in fixed,
permeabilised cells that were blocked with BSA (negatively
charged). One way to assess the non-specific binding of these
Qdot-Abs to cells would be to use flow cytometry.
Beyond those commercially available Qdots, there have been a
number of ICC protocols published for the labelling of differ-
ent proteins with Qdot-Abs [6,20,24]. These reports, however,
were mostly focused on the unproblematic labelling of tubulin
for their proof-of-principle experiments. We suggest that future
developments of Qdot-Abs include other more challenging
targets as benchmarks, for example, those evaluated in this
article. The ideal scenario would be a toolbox of commercially
available Qdot-Abs that can be consistently used to label any bi-
ological structure of interest and not just tubulin and extracel-
lular targets.
Methods
Cell culture
Human cervix epithelioid carcinoma (HeLa, ECACC number
930210a3) cells were cultured in a 75 cm2 flask at 37 °C with
5% CO2, minimum essential media (MEM, Life Technologies,
UK) supplemented with 10% (v/v) foetal calf serum (FCS), and
1% non-essential amino acids (NEAA). Cells were split
1,000,000 cells/mL when ≥80% confluent with trypsin-EDTA.
Rat mammary (Rama) 27 fibroblasts were cultured in a 75 cm2
flask at 37 °C with 5% CO2, Dulbecco's modified Eagle's medi-
um (DMEM, Life Technologies, UK) supplemented with
10% (v/v) FCS (Life Technologies, UK), 0.75% (w/v) sodium
bicarbonate, 4 mM L-glutamine, 50 ng/mL insulin, and
50 ng/mL hydrocortisone (Sigma-Aldrich, UK), as described
previously [40]. Cells were split 1:8 when ≥60% confluent with
trypsin-EDTA. A stable cell line TC7 3xGFP (expressing
tubulin-GFP) was cultured in a 75 cm2 flask at 37 °C with
5% CO2, MEM (Life Technologies, UK) supplemented with
10% (v/v) FCS, 1% NEAA, and genetitin (Sigma-Aldrich, UK),
as described previously [41]. Cells were split 1:15 when ≥80%
confluent with trypsin-EDTA.
Transfection
HeLa cells were seeded onto 16 mm glass coverslips
(100,000 cells/mL) in a 12-well plate and transfected with
pG-EGFP-A (soluble GFP) or pG-EGFP-HIF2α (EGFP-HIF2α)
using FuGENE6 transfection reagent (Roche Limited, UK),
following the manufacturer's protocol (3:1 transfection reagent/
DNA plasmid).
Site click conjugation of Qdot625 to anti-GFP
Following the manufacturer's protocol, a commercial site-click
Qdot 625 antibody conjugation kit (Thermo Fisher Scientific,
UK) was used to conjugate a primary mouse (clones 7.1 and
13.1) anti-GFP antibody (Roche Limited, UK) to dibenzocy-
clooctyne (DIBO) modified Qdot 625. The concentration of the
Qdots in the conjugate was calculated to be 3 μM using the
equation c = A/ε, where c is the concentration of DIBO-modi-
fied Qdot 625 attached to the primary antibody, A is the absor-
bance of Qdot 625, and ε is the extinction coefficient of Qdot
625 (500,000 M−1·cm−1). The absorbance between 605–612 nm
(step 10 nm) was measured to be 1.5 a.u. using a quartz cuvette
with a 1 cm path length, on a SpectraMax 34 Plus spectropho-
tometer (Molecular Devices, UK).
Immunofluorescence
An overview of the immunofluorescence procedure is shown in
Figure 8. Briefly, cells were seeded onto glass coverslips and
grown until confluent, washed once in phosphate buffered
saline (PBS) (37 °C), and fixed in 4% (w/v) paraformaldehyde
(PFA) for 10 min or 100% ice cold methanol (5 min). Cells
were washed 3× in PBS (5 min), permeabilised with 0.25%
Triton X-100 in PBS for 60 min (except methanol fixation),
washed again 3× in PBS (5 min), and incubated with 6% bovine
serum albumin (BSA, Sigma-Aldrich, UK) in PBS (60 min).
Primary antibodies produced in mouse (anti-β-tubulin TUB 2.1,
Sigma-Aldrich, UK; anti-GFP Roche Limited, UK; anti-SC35,
Abcam, UK; and anti-talin, Sigma-Aldrich, UK), those pro-
duced in rabbit (anti-fibronectin, Sigma-Aldrich, UK), and
biotinylated anti-GFP (Abcam, UK) were diluted 1:100 in
6% BSA and incubated overnight at 4 °C. Cells were washed
3× in PBS (5 min) and incubated simultaneously with either a
mixture of Donkey anti-mouse IgG H+L secondary antibody
Qdot 625 conjugate, Qdot 625 anti-GFP conjugate, F(ab')2-
Goat anti-rabbit IgG H+L secondary antibody Qdot 625 conju-
gate, or Qdot 625 streptavidin conjugate (Thermo Fisher Scien-
tific, UK), diluted 1:50 to 20 nM in 6% BSA, and goat anti-
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Figure 8: Immunofluorescence protocol. The pink boxes show the method for use with a primary antibody and Qdot 625/Fluorescent dye conjugated
to a secondary antibody, green box is for methanol fixation, yellow boxes for the anti-GFP Qdot 625 conjugate, and blue boxes are for biotinylated pri-
mary antibody with Qdot 625 streptavidin conjugate.
rabbit Alexa Fluor 488 or goat anti-mouse Alexa Fluor 488
(Thermo Fisher Scientific, UK), diluted 1:500 to 4 µg/mL in
6% BSA; or anti-mouse cyanine 3 (Sigma-Aldrich, UK) diluted
1:500 to 4 µg/mL in 6% BSA, at room temperature (60 min).
Before preparation of the Qdot 625 conjugated secondary anti-
body, the vial was centrifuged at 5,000 g for 3 min to remove
any aggregates. After 3 washes in PBS (10 min), coverslips
were mounted onto slides with Dako fluorescent mounting
media (Dako, UK), and stored at 4 °C. A negative control of
Qdot 625 conjugated antibody only was also prepared to show
any background staining.
Wide-field imaging
Images were taken on a wide-field epifluorescence microscope
(Carl Zeiss Axio Observer Z.1, Germany) with a 16 μm
512 × 512 pixel sensitive electron-multiplying charge-coupled
device (EMCCD) camera (Andor iXon 897 Ultra), polychro-
matic mercury arc lamp, 39106-AT-QDot 625 filter set
(Chroma Technology Corporation, USA), and a 100× 1.45 NA
oil-immersion objective. Fluorescent and corresponding bright-
field images were acquired using Micro-Manager software [42].
The same acquisition settings were used for each set of images,
including lamp power, exposure time, and gain.
Co-localisation analysis
Pearson correlation coefficient scatter plots of Qdot 625 and
Alexa Fluor 488/GFP were produced using a custom-made
Matlab code [43]. Manders’ correlation coefficients were deter-
mined using a Just Another Co-localization Plugin (JACoP)
[29] in FIJI [44].
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